KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2025)

Sarepta Therapeutics has reported Raw Materials over the past 10 years, most recently at $141.3 million for Q4 2025.

  • Quarterly results put Raw Materials at $141.3 million for Q4 2025, down 49.55% from a year ago — trailing twelve months through Dec 2025 was $141.3 million (down 49.55% YoY), and the annual figure for FY2025 was $141.3 million, down 49.55%.
  • Raw Materials for Q4 2025 was $141.3 million at Sarepta Therapeutics, down from $325.5 million in the prior quarter.
  • Over the last five years, Raw Materials for SRPT hit a ceiling of $325.5 million in Q3 2025 and a floor of $40.2 million in Q3 2021.
  • Median Raw Materials over the past 5 years was $199.9 million (2021), compared with a mean of $187.9 million.
  • Peak annual rise in Raw Materials hit 294.05% in 2022, while the deepest fall reached 74.29% in 2022.
  • Sarepta Therapeutics' Raw Materials stood at $230.2 million in 2021, then crashed by 74.29% to $59.2 million in 2022, then soared by 126.36% to $134.0 million in 2023, then surged by 109.05% to $280.0 million in 2024, then crashed by 49.55% to $141.3 million in 2025.
  • The last three reported values for Raw Materials were $141.3 million (Q4 2025), $325.5 million (Q3 2025), and $314.9 million (Q2 2025) per Business Quant data.